Table S8. Top 20 most significant GO Terms for GeneIDs either hyper- or hypomethylated in M0-P and M1 tumor samples. (PDF 54 kb
Table S1. List of primers used for pyrosequencing and quantitative RT-PCR. (XLSX 10 kb
Figures S3. Scatter plots showing relationship between mRNA expression levels and methylation in fou...
Figure S2. Six DNA methylation sites of CLDN7 promoter that not significantly hypermethylated in TCG...
Table S6. Clinicopathological parameters for tumors included in the heterogeneity analysis. (PDF 65 ...
Table S7. Cox’s proportional hazard regression analysis for progress free survival (PFS) in 87 M0 cc...
Table S5. Cox’s proportional hazard regression analysis for progress free survival (PFS) in 87 M0 cc...
Table S4. Cox’s proportional hazard regression analysis for cancer specific survival (CSS) in 115 cc...
Figure S4. Distribution of hyper- and hypomethylated CpGs in patients with or without specific genom...
Figure S1. Single nucleotide polymorphism (SNP) analysis. SNP analysis of 65 genotyping probes on th...
Table S2. Comparison of CNV results gained from HumanMethylation450K and HumanCytoSNP-12 arrays in 5...
Figure S5. Correlations between number of hypomethylated CpGs and number of genetic aberrations and ...
Figure S2. Copy number variation (CNV) analysis. CNV analysis of twelve chromosome regions previousl...
Figure S3. Survival analysis based on Risk Score at diagnosis. Kaplan-Meier cancer specific survival...
Additional file 1: Table S1. The location of patient with metastasizing cancer. Figure S1. Demethyl...
Figure S4. The CLDN7 promoter DNA methylation site, cg00072720, was associated with poor overall sur...
Table S1. List of primers used for pyrosequencing and quantitative RT-PCR. (XLSX 10 kb
Figures S3. Scatter plots showing relationship between mRNA expression levels and methylation in fou...
Figure S2. Six DNA methylation sites of CLDN7 promoter that not significantly hypermethylated in TCG...
Table S6. Clinicopathological parameters for tumors included in the heterogeneity analysis. (PDF 65 ...
Table S7. Cox’s proportional hazard regression analysis for progress free survival (PFS) in 87 M0 cc...
Table S5. Cox’s proportional hazard regression analysis for progress free survival (PFS) in 87 M0 cc...
Table S4. Cox’s proportional hazard regression analysis for cancer specific survival (CSS) in 115 cc...
Figure S4. Distribution of hyper- and hypomethylated CpGs in patients with or without specific genom...
Figure S1. Single nucleotide polymorphism (SNP) analysis. SNP analysis of 65 genotyping probes on th...
Table S2. Comparison of CNV results gained from HumanMethylation450K and HumanCytoSNP-12 arrays in 5...
Figure S5. Correlations between number of hypomethylated CpGs and number of genetic aberrations and ...
Figure S2. Copy number variation (CNV) analysis. CNV analysis of twelve chromosome regions previousl...
Figure S3. Survival analysis based on Risk Score at diagnosis. Kaplan-Meier cancer specific survival...
Additional file 1: Table S1. The location of patient with metastasizing cancer. Figure S1. Demethyl...
Figure S4. The CLDN7 promoter DNA methylation site, cg00072720, was associated with poor overall sur...
Table S1. List of primers used for pyrosequencing and quantitative RT-PCR. (XLSX 10 kb
Figures S3. Scatter plots showing relationship between mRNA expression levels and methylation in fou...
Figure S2. Six DNA methylation sites of CLDN7 promoter that not significantly hypermethylated in TCG...
DOI
Add to ORKG